Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 644

1.

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.

Cooper DA, Heera J, Ive P, Botes M, Dejesus E, Burnside R, Clumeck N, Walmsley S, Lazzarin A, Mukwaya G, Saag M, van Der Ryst E.

AIDS. 2014 Mar 13;28(5):717-25. doi: 10.1097/QAD.0000000000000131.

PMID:
24983542
[PubMed - in process]
Free PMC Article
2.

Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial.

Achhra AC, Boyd MA, Law MG, Matthews GV, Kelleher AD, Cooper DA.

PLoS One. 2014 Jun 26;9(6):e99530. doi: 10.1371/journal.pone.0099530. eCollection 2014.

PMID:
24968324
[PubMed - in process]
Free PMC Article
3.

Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.

Cooper DA, Kimmel HL, Manvich DF, Schmidt KT, Weinshenker D, Howell LL.

J Pharmacol Exp Ther. 2014 Jul;350(1):144-52. doi: 10.1124/jpet.113.212357. Epub 2014 May 9.

PMID:
24817036
[PubMed - in process]
4.

Human antigen-specific CD4(+) CD25(+) CD134(+) CD39(+) T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses.

Seddiki N, Cook L, Hsu DC, Phetsouphanh C, Brown K, Xu Y, Kerr SJ, Cooper DA, Munier CM, Pett S, Ananworanich J, Zaunders J, Kelleher AD.

Eur J Immunol. 2014 Jun;44(6):1644-61. doi: 10.1002/eji.201344102. Epub 2014 Apr 29.

PMID:
24752698
[PubMed - in process]
5.

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.

Haskelberg H, Cordery DV, Amin J, Kelleher AD, Cooper DA, Emery S; STEAL Study Group.

PLoS One. 2014 Mar 28;9(3):e93333. doi: 10.1371/journal.pone.0093333. eCollection 2014.

PMID:
24681993
[PubMed - in process]
Free PMC Article
6.

Determinants of suicide and accidental or violent death in the Australian HIV Observational Database.

McManus H, Petoumenos K, Franic T, Kelly MD, Watson J, O'Connor CC, Jeanes M, Hoy J, Cooper DA, Law MG; Australian HIV Observational Database.

PLoS One. 2014 Feb 19;9(2):e89089. doi: 10.1371/journal.pone.0089089. eCollection 2014.

PMID:
24586519
[PubMed - in process]
Free PMC Article
7.

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.

ENCORE1 Study Group, Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, Young B, Shahar E, Wolff M, Gazzard B, Read T, Hill A, Cooper DA, Emery S.

Lancet. 2014 Apr 26;383(9927):1474-82. doi: 10.1016/S0140-6736(13)62187-X. Epub 2014 Feb 10. Erratum in: Lancet. 2014 Apr 26;383(9927):1464.

PMID:
24522178
[PubMed - indexed for MEDLINE]
8.

Ribonuclease L and metal-ion-independent endoribonuclease cleavage sites in host and viral RNAs.

Cooper DA, Jha BK, Silverman RH, Hesselberth JR, Barton DJ.

Nucleic Acids Res. 2014 Apr;42(8):5202-16. doi: 10.1093/nar/gku118. Epub 2014 Feb 5.

PMID:
24500209
[PubMed - in process]
Free PMC Article
9.

HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.

Murray JM, Zaunders JJ, McBride KL, Xu Y, Bailey M, Suzuki K, Cooper DA, Emery S, Kelleher AD, Koelsch KK; PINT Study Team.

J Virol. 2014 Mar;88(6):3516-26. doi: 10.1128/JVI.03331-13. Epub 2014 Jan 8.

PMID:
24403590
[PubMed - indexed for MEDLINE]
10.

Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy.

Hsu DC, Kerr SJ, Thongpaeng P, Iampornsin T, Pett SL, Zaunders JJ, Avihingsanon A, Ubolyam S, Ananworanich J, Kelleher AD, Cooper DA.

J Infect. 2014 Apr;68(4):344-54. doi: 10.1016/j.jinf.2013.11.016. Epub 2013 Dec 8.

PMID:
24325926
[PubMed - in process]
11.

Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing.

Suzuki K, Hattori S, Marks K, Ahlenstiel C, Maeda Y, Ishida T, Millington M, Boyd M, Symonds G, Cooper DA, Okada S, Kelleher AD.

Mol Ther Nucleic Acids. 2013 Dec 3;2:e137. doi: 10.1038/mtna.2013.64.

PMID:
24301868
[PubMed]
Free PMC Article
12.

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.

Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter K; SPARTAC Trial Investigators.

AIDS. 2014 Mar 27;28(6):869-74. doi: 10.1097/QAD.0000000000000155.

PMID:
24300544
[PubMed - in process]
13.

HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

Martin A, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second-Line Study Team.

PLoS One. 2013 Oct 30;8(10):e77138. doi: 10.1371/journal.pone.0077138. eCollection 2013.

PMID:
24204757
[PubMed - in process]
Free PMC Article
14.

Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons.

Sabin CA, Cooper DA, Collins S, Schechter M.

AIDS. 2013 Jul 31;27(12):1839-46. Review.

PMID:
24179998
[PubMed - indexed for MEDLINE]
15.

Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.

Hsu DC, Kerr SJ, Iampornsin T, Pett SL, Avihingsanon A, Thongpaeng P, Zaunders JJ, Ubolyam S, Ananworanich J, Kelleher AD, Cooper DA.

PLoS One. 2013 Oct 10;8(10):e77479. doi: 10.1371/journal.pone.0077479. eCollection 2013.

PMID:
24130889
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients.

Avihingsanon A, Kerr SJ, Punyawudho B, van der Lugt J, Gorowara M, Ananworanich J, Lange JM, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K.

AIDS Res Hum Retroviruses. 2013 Dec;29(12):1541-6. doi: 10.1089/aid.2013.0069. Epub 2013 Oct 2.

PMID:
24088045
[PubMed - indexed for MEDLINE]
17.

SPRING-2 the future of antiretroviral therapy.

Boyd MA, Cooper DA.

Lancet Infect Dis. 2013 Nov;13(11):908-9. doi: 10.1016/S1473-3099(13)70194-4. Epub 2013 Sep 25. No abstract available.

PMID:
24074643
[PubMed - indexed for MEDLINE]
18.

The majority of HIV type 1 DNA in circulating CD4+ T lymphocytes is present in non-gut-homing resting memory CD4+ T cells.

McBride K, Xu Y, Bailey M, Seddiki N, Suzuki K, Murray JM, Gao Y, Yan C, Cooper DA, Kelleher AD, Koelsch KK, Zaunders J.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1330-9. doi: 10.1089/AID.2012.0351.

PMID:
23971972
[PubMed - indexed for MEDLINE]
19.

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.

Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso W, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second Line study team.

AIDS. 2013 Sep 24;27(15):2403-11. doi: 10.1097/01.aids.0000432534.47217.b4.

PMID:
23921615
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting.

Murray JM, Zaunders JJ, Koelsch KK, Natarajan V, Badralmaa Y, McBride K, Carrera A, Cooper DA, Emery S, Kelleher AD.

AIDS Res Hum Retroviruses. 2013 Dec;29(12):1621-5. doi: 10.1089/AID.2013.0132. Epub 2013 Aug 9.

PMID:
23844947
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk